Clinical Trials Logo

Lymphoma clinical trials

View clinical trials related to Lymphoma.

Filter by:

NCT ID: NCT05239676 Recruiting - Lymphoma Clinical Trials

Autologous Hematopoietic Stem Cell Transplantation Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Malignant Lymphoma

Start date: February 28, 2022
Phase: Early Phase 1
Study type: Interventional

Clinical Study on the Safety and Effectiveness of Autologous Hematopoietic Stem Cell Transplantation Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Malignant Lymphoma

NCT ID: NCT05237245 Recruiting - HTLV-1 Infection Clinical Trials

Clinico-biological Characterization and Survival of Patients With Adult T-cell Leukemia / Lymphoma (ATL) and Patients Chronically Infected With the HTLV-1 Virus (HTLV-OBS)

HTLV-OBS
Start date: March 23, 2022
Phase:
Study type: Observational

The purpose of this study is to evaluate the outcome (survival) of Adult T-cell leukemia / lymphoma (ATL) patients who receive or not specific treatment for their hemopathy (cohort 1) and the outcome (survival) of HTLV-1 chronically infected patients with / without extra-haematological disorders (cohort 2).

NCT ID: NCT05234684 Recruiting - Clinical trials for Diffuse Large B Cell Lymphoma (DLBCL)

A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma

BELIEVE-01
Start date: November 2, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of orelabrutinib combined with R-CHOP regimen versus placebo with R-CHOP in the treatment of treatment-naïve patients with MCD subtype DLBCL.

NCT ID: NCT05231135 Recruiting - Clinical trials for AIDS Related Lymphoma

A Registry Study on HIV-related Lymphoma

Start date: August 25, 2021
Phase:
Study type: Observational [Patient Registry]

Retrospective und prospective registry on HIV-associated lymphoma. Data on characteristics, type and toxicity of treatment and outcome of patients with HIV-lymphoma will be collected.

NCT ID: NCT05230680 Recruiting - T Cell Lymphoma Clinical Trials

Azacitidine-CHOP for Patients With Nodal T-cell Lymphoma With T-follicular Helper Phenotype (ACANTUS)

Start date: July 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Induction treatment (every 3 weeks, total 6 cycles) - Azacitidine D-2, -1, 1 (level 1: 50mg/m2, level 2: 75mg/m2, level 3: 100mg/m2, level 4: 125mg/m2) - Cyclophosphamide 750mg/m2 d1 - Doxorubicin 50 mg/m2 d1 - Vincristine 1.4 mg/m2 (Max: 2 mg) d1 - Prednisolone 100mg PO d1-5 Maintenance treatment (every 4 weeks, total 12 cycles) - Azacitidine 75mg/m2 d1-5

NCT ID: NCT05228158 Recruiting - Clinical trials for Lymphoma, Follicular

A Study of Tazemetostat on Safety in Participants With Relapsed or Refractory Follicular Lymphoma With Enhancer of Zeste Homolog 2 (EZH2) Gene Mutation in Japan

Start date: August 16, 2021
Phase:
Study type: Observational

The primary purpose of the study is to investigate the safety of tazemetostat in participants with relapsed or refractory follicular lymphoma with EZH2 gene mutation under daily clinical practice.

NCT ID: NCT05225584 Recruiting - Solid Tumors Clinical Trials

Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors

Start date: May 19, 2022
Phase: Phase 1
Study type: Interventional

This Phase 1a/1b study will evaluate the safety, tolerability and the pharmacokinetics/pharmacodynamics (PK/PD) of KT-333 in Adult patients with Relapsed or Refractory (R/R) Lymphomas, Large Granular Lymphocytic Leukemia (LGL-L), T-cell prolymphocytic leukemia (T-PLL), and Solid Tumors. The Phase 1a stage of the study will explore escalating doses of single-agent KT-333. The Phase Ib stage will consist of 4 expansion cohorts to further characterize the safety, tolerability and the pharmacokinetics/pharmacodynamics (PK/PD) of KT-333 in Peripheral T-cell Lymphoma (PTCL), Cutaneous T-Cell Lymphoma (CTCL), LGL-L, and solid tumors.

NCT ID: NCT05223413 Recruiting - Lymphoma Clinical Trials

REmote iSchemic condItioning in Lymphoma PatIents REceiving ANthraCyclinEs

RESILIENCE
Start date: January 18, 2022
Phase: N/A
Study type: Interventional

Multinational, prospective, proof of concept phase II, double-blinded, sham-controlled, randomized clinical trial (RCT) to evaluate the efficacy and safety of Remote Ischaemic PreConditioning (RIPC) in Lymphoma patients receiving anthracyclines.

NCT ID: NCT05221645 Recruiting - Clinical trials for Diffuse Large B Cell Lymphoma

Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma

P+R-ICE
Start date: June 27, 2022
Phase: Phase 2
Study type: Interventional

This is an open-label, multicentre, randomised phase II trial in relapsed or refractory diffuse large B-cell lymphoma.

NCT ID: NCT05219513 Recruiting - Clinical trials for Lymphoma, Non-Hodgkin

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Start date: February 18, 2022
Phase: Phase 1
Study type: Interventional

This is a first-in human, open-label, Phase 1 dose-escalation study in order to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) for intravenous (IV) and/or subcutaneous (SC) dosing schemes of this combination treatment, and to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of this combination treatment in participants with relapsed/refractory B-cell non Hodgkin lymphoma (r/r NHL).